trending Market Intelligence /marketintelligence/en/news-insights/trending/lwgrskxmyjwktwbujqd81g2 content esgSubNav
In This List

Cooper's fiscal Q2 profit up YOY; FY'18 revenue guidance narrows

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Cooper's fiscal Q2 profit up YOY; FY'18 revenue guidance narrows

Cooper Cos. Inc. said non-GAAP EPS for the fiscal second quarter ended April 30 rose 15% year over year to $2.86 from $2.50 last year.

The S&P Capital IQ consensus normalized EPS estimate for the quarter was $2.84.

On a GAAP basis, net income attributable to Cooper stockholders fell to $60.9 million, or $1.23 per share, from $104.9 million, or $2.12 per share in the year-ago period.

The Pleasanton, Calif.-based medical device maker's net sales for the quarter increased 21% year over year to $631.3 million.

The company narrowed its fiscal 2018 revenue forecast to $2.52 billion to $2.55 billion, compared to the $2.51 billion to $2.56 billion announced earlier.

Cooper also reiterated its full-year non-GAAP EPS at $11.70 and $11.90. The S&P Capital IQ consensus normalized EPS estimate for the fiscal year 2018 is $11.79.